<h1>Activity Description</h1>
Diabetes screening for people with schizophrenia or bipolar disease who are using antipsychotic medication.
<table>
<thead>
<tr>
<th>Activity ID</th>
<th>Activity Weighting</th>
<th>Sub-Category Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA_BMH_1</td>
<td>Medium</td>
<td>Behavioral and Mental Health</td>
</tr>
</tbody>
</table>
<h1></h1>
<h1>Objective & Validation Documentation</h1>
Objective: Improve rates of screening for patients with schizophrenia or bipolar disorder, who have higher risk or higher prevalence of diabetes relative to the general population, thus increasing eligible clinicians’ ability to detect and respond early to positive diagnoses, potentially reducing the burden and complications of the disease.
Validation Documentation: Demonstration of diabetes screening for patients with schizophrenia or bipolar disease who are using antipsychotic medication. Include both of the following elements:
1) Identification of patients – Evidence of regular identification of patients with schizophrenia or bipolar disease who are using antipsychotic medication and who should receive diabetes screening (e.g., report from the electronic health record [EHR], flag or note in the EHR or medical chart, registry, other population health management tracking report); AND
2) Documented diabetes screenings – Percentage of patients identified in element “1)” (for example, annually) who receive a diabetes screening, with supporting documentation from EHR reports, medical charts, or claims.